Page last updated: 2024-12-04

triphosphoric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Triphosphoric acid (H5P3O10) is an inorganic compound that can be considered a derivative of phosphoric acid (H3PO4). It is a strong acid, and its structure features three phosphate groups linked together by oxygen atoms. Triphosphoric acid is commonly synthesized by the dehydration of orthophosphoric acid (H3PO4) under specific conditions, such as heating in the presence of a dehydrating agent. It is found in nature as a component of certain minerals and plays a significant role in various biological processes. For instance, it is involved in the formation of adenosine triphosphate (ATP), the primary energy carrier in living organisms. Moreover, triphosphoric acid is used in various industrial applications, including the production of fertilizers, detergents, and pharmaceuticals. The study of triphosphoric acid is crucial for understanding its role in biological and industrial systems and for developing new applications in fields like agriculture, medicine, and materials science.'

triphosphoric acid: used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID983
CHEMBL ID1230191
CHEBI ID39949
MeSH IDM0047397

Synonyms (30)

Synonym
CHEMBL1230191
C02174
C00404
triphosphoric acid
inorganic triphosphate
oligophosphate ,
C00536
catena-triphosphoric acid
h5p3o10
bis(dihydroxidodioxidophosphato)hydroxidooxidophosphorus
mu-[hydroxidotrioxidophosphato(2-)-1kappao,2kappao]-bis(dihydroxidooxidophosphorus)
triphosphorsaeure
1,7-dihydrido-2,4,6-trihydroxido-2,4,6-trioxido-1,3,5,7-tetraoxy-2,4,6-triphosphy-[7]catena
10380-08-2
CHEBI:39949 ,
pentahydroxido-1kappa(2)o,2kappao,3kappa(2)o-di-mu-oxido-trioxido-1kappao,2kappao,3kappao-triphosphorus
acide triphosphorique
DB03896
bis(phosphonooxy)phosphinic acid
diphosphono hydrogen phosphate
unii-nu43iag5bc
einecs 233-840-3
nu43iag5bc ,
triphosphoric acid (h5p3o10)
DTXSID7047483
FT-0699303
triphoshoric acid
Q2823316
triphosphoricacid
{[hydroxy(phosphonooxy)phosphoryl]oxy}phosphonic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The increased mortality in mice given Cd + NTA or Cd + STPP may be due to an initially high accumulation of cadmium in liver, which may exceed the upper limit for metallothionein synthesis, whereby toxic damage of the hepatic cells and leakage of cadmium from the liver would occur."( Influence of chelating agents on toxicity and distribution of cadmium among proteins of mouse liver and kidney following oral or subcutaneous exposure.
Engström, B, 1981
)
0.26
" This work investigates the preparation and characterization of nanoparticles composed of chitosan and sodium tripolyphosphate (TPP) to produce an efficient herbicidal formulation that was less toxic and could be used for safer control of weeds in agriculture."( Chitosan/tripolyphosphate nanoparticles loaded with paraquat herbicide: an environmentally safer alternative for weed control.
de Lima, R; Fraceto, LF; Greiner, R; Grillo, R; Nishisaka, CS; Oehlke, K; Pereira, AE, 2014
)
0.4
" The ecotoxicity and genotoxicity assays showed that humic substances can decrease the toxic effects of nanoparticles containing paraquat."( Chitosan nanoparticles loaded the herbicide paraquat: the influence of the aquatic humic substances on the colloidal stability and toxicity.
Campos, EV; Chalupe, VC; Clemente, Z; de Lima, R; de Oliveira, JL; Fraceto, LF; Greiner, R; Grillo, R; Jonsson, CM; Nishisaka, CS; Oehlke, K; Rosa, AH; Sanches, G, 2015
)
0.42
" Both loaded and unloaded NC_PCL were the most toxic formulations to developmental rate, significantly reducing worms length, even at low concentrations."( Safety assessment of nanopesticides using the roundworm Caenorhabditis elegans.
Ávila, DS; Campos, EV; Fraceto, LF; Jacques, MT; Oliveira, JL, 2017
)
0.46
"As a potent herbicide capable of contaminating water and soil environments, paraquat, which is still widely used worldwide, is toxic to mammals, algae, aquatic animals, etc."( Pectin/Chitosan/Tripolyphosphate Nanoparticles: Efficient Carriers for Reducing Soil Sorption, Cytotoxicity, and Mutagenicity of Paraquat and Enhancing Its Herbicide Activity.
Birjandi, M; Davari, B; Heydari, R; Kordi, S; Maleki, A; Mohammadi, E; Pajouhi, N; Rashidipour, M; Rasoulian, B; Rezaee, R, 2019
)
0.51
" The corneal hydration and histopathology of excised goat cornea revealed safe to the cornea."( Stimulus Responsive Ocular Gentamycin-Ferrying Chitosan Nanoparticles Hydrogel: Formulation Optimization, Ocular Safety and Antibacterial Assessment.
Afzal, M; Alhakamy, NA; Alharbi, KS; Alotaibi, NH; Alruwaili, NK; Alshehri, S; Alzarea, AI; Elmowafy, M; Imam, SS; Zafar, A, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
" Parameter estimates were then combined with a published population pharmacokinetic model in Chinese patients to predict human intracellular FAVI-RTP."( Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
Khoo, SH; Owen, A; Pertinez, H; Rajoli, RKR, 2021
)
0.62
" Therefore, physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) models for encapsulated and unencapsulated dFdC were constructed considering the tumor dFdCTP concentration as an index of antitumor activity."( A physiologically based pharmacokinetic and pharmacodynamic model for disposition of FF-10832.
Ioroi, T; Kato, Y; Kimura, T; Kitahara, H; Masuo, Y; Matsumoto, T; Tanaka, A; Yamakawa, T, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" The aim of the present study was to investigate the remineralization of demineralized dentin slices using CPP-ACP combined with TPP, and the research hypothesis was that CPP-ACP combined with TPP could result in extrafibrillar and intrafibrillar remineralization of dentin."( Remineralization of dentin slices using casein phosphopeptide-amorphous calcium phosphate combined with sodium tripolyphosphate.
Bian, M; Ge, X; Li, N; Lu, J; Xu, T; Yu, J; Zhou, Z, 2020
)
0.56
"Treatment with CPP-ACP combined with TPP occluded the dentinal tubules and resulted in remineralization of collagen fibrils."( Remineralization of dentin slices using casein phosphopeptide-amorphous calcium phosphate combined with sodium tripolyphosphate.
Bian, M; Ge, X; Li, N; Lu, J; Xu, T; Yu, J; Zhou, Z, 2020
)
0.56
"CPP-ACP combined with TPP has a good remineralization effect on demineralized dentin slices."( Remineralization of dentin slices using casein phosphopeptide-amorphous calcium phosphate combined with sodium tripolyphosphate.
Bian, M; Ge, X; Li, N; Lu, J; Xu, T; Yu, J; Zhou, Z, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"To have advantages of reduced dosing frequency, improved bioavailability and effective delivery system of Cefuroxime Axetil, a Chitosan based intragastric sustained release microbead formulation of Cefuroxime Axetil was developed."( Chitosan-based intragastric delivery of cefuroxime axetil: development and in-vitro evaluation of mucoadhesive approach.
Nagar, M; Yadav, AV, 2012
)
0.38
"The aim of this study was to assess the feasibility of microparticles for dissolution enhancement and oral bioavailability of curcumin (Cur)."( Chitosan microparticles for oral bioavailability improvement of the hydrophobic drug curcumin.
Sun, L; Sun, Y; Tan, F; Wan, S, 2012
)
0.38
" The in vivo ophthalmic drug absorption study performed on rabbits indicated that DC-TMCNs could improve ophthalmic bioavailability of DC."( Development and Evaluation of Diclofenac Sodium Loaded-N-Trimethyl Chitosan Nanoparticles for Ophthalmic Use.
Asasutjarit, R; Fuongfuchat, A; Kewsuwan, P; Ritthidej, GC; Theerachayanan, T; Veeranodha, S, 2015
)
0.42
"An encapsulated system for cryptdin-2 (a Paneth cell antimicrobial peptide) was developed, with a view to help it sustain adverse gut conditions and to ensure its bioavailability on oral administration."( Improved oral therapeutic potential of nanoencapsulated cryptdin formulation against Salmonella infection.
Arora, S; Bhogal, A; Kaur, IP; Pandey, SK; Rishi, P; Verma, I, 2015
)
0.42
" The purpose of the current research work was to develop and evaluate Bay41-4109 loaded chitosan nanoparticles to increase the solubility and bioavailability for treatment of HBV."( Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor.
An, S; Guo, Y; Hou, H; Hu, S; Jiang, C; Jiang, X; Lu, Y; Xue, M; Zhang, Y; Zhou, X, 2015
)
0.42
" This approach can improve the bioavailability and sustained release of phytochemicals having lower bioavailability."( Encapsulation and release studies of strawberry polyphenols in biodegradable chitosan nanoformulation.
Brar, SK; Das, RK; Marques, C; Pulicharla, R; Rouissi, T, 2016
)
0.43
" Significantly higher brain/blood ratio and 2 folds higher nasal bioavailability in brain with QF-NP in comparison to drug solution following intranasal administration revealed preferential nose to brain transport bypassing blood-brain barrier and prolonged retention of QF at site of action suggesting superiority of chitosan as permeability enhancer."( "Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* ".
Khunt, D; Misra, M; Padh, H; Shah, B, 2016
)
0.43
" However, loss of carrier stability against biological environments induces low bioavailability of encapsulated drugs after oral administration."( Novel amphiphilic chitosan nanocarriers for sustained oral delivery of hydrophobic drugs.
Kashanian, S; Motiei, M, 2017
)
0.46
"The poor retention and penetration are the major issues in the bioavailability of drugs through ocular route."( Development of Timolol Maleate Loaded Chitosan Nanoparticles For Improved Ocular Delivery.
Kaushik, D; Pandey, P; Saroha, A, 2017
)
0.46
" To improve oral bioavailability of dioscorins in the intestine, recombinant dioscorin (rDioscorin) was coated with N,N,N-trimethyl chitosan (TMC) and tripolyphosphate (TPP), resulting in the formation of TMC-rDio-TPP nanoparticles (NPs)."( Development of Yam Dioscorin-Loaded Nanoparticles for Paracellular Transport Across Human Intestinal Caco-2 Cell Monolayers.
Hsieh, HL; Lee, CH; Lin, KC, 2018
)
0.48
" However, no oral protein formulations are commercially available currently due to hostile gastrointestinal (GI) barriers resulting in insignificant oral bioavailability of macromolecular drugs."( Scalable Manufacturing of Enteric Encapsulation Systems for Site-Specific Oral Insulin Delivery.
Chen, Y; Le, Z; Leong, KW; Liu, L; Liu, Z; Mao, HQ; Sun, L; Tian, H, 2019
)
0.51
"Chitosan (CS)-based hydrogels with different structures were prepared to ensure the bioavailability of bioactive components."( Effect of crosslinking processing on the chemical structure and biocompatibility of a chitosan-based hydrogel.
Liang, G; Situ, W; Xiang, T; Yang, J, 2021
)
0.62
" Ginsenoside Rb3 (G-Rb3) is one of the main components of Ginseng and exhibits poor oral bioavailability but still exerts regulate energy metabolism effects in some diseases."( Nanoparticle conjugation of ginsenoside Rb3 inhibits myocardial fibrosis by regulating PPARα pathway.
Gao, W; Han, X; Huang, L; Ji, H; Li, X; Li, Z; Liu, C; Man, S; Pecoraro, L; Qiao, O; Wang, J; Wang, W; Zhang, X; Zhang, Y, 2021
)
0.62
" Many studies have focused on improving the bioavailability of silymarin due to its wide range of efficacy and low bioavailability."( Neural Network-based Optimization of
Hanafi, A; Rezazadeh, S; Safa, KD, 2023
)
0.91
" However, its limited stability and bioavailability posed significant challenges for further applications."( Preparation, characterization and protective effect of chitosan - Tripolyphosphate encapsulated dihydromyricetin nanoparticles on acute kidney injury caused by cisplatin.
Dong, L; Fu, H; Li, M; Li, Y; Luo, J; Shi, F; Shu, G; Tang, H; Yan, Q; Ye, G; Yin, H; Zhang, W; Zhao, L; Zhao, X; Zhong, X, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
"These results are consistent with once daily CLV dosing currently being used in Phase III clinical studies."( Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes.
Furman, PA; Murakami, E; Niu, C, 2008
)
0.35
" Our SAR studies ultimately led to compounds that gave high levels of NTP in hamster and rat liver after subcutaneous dosing and that were devoid of the toxic phenol moiety usually found in ProTides."( Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
Attenni, B; Di Marco, A; Donghi, M; Fiore, F; Gardelli, C; Gennari, N; Giuliano, C; Harper, S; Laufer, R; Leone, JF; MacCoss, M; Marcucci, I; Meppen, M; Narjes, F; Olsen, DB; Pacini, B; Pucci, V; Rowley, M, 2009
)
0.35
" These parameters can be judiciously used in predicting and modifying drug release from dosage forms."( Cross-linked chitosan films: effect of cross-linking density on swelling parameters.
Rana, V; Tiwary, AK, 2010
)
0.36
" The preparation method of SH-NiMS is stable and reliable to use, which provide a new way to develop new dosage form."( [Preparation of scopolamine hydrobromide nanoparticles-in-microsphere system].
Hu, JH; Li, FQ; Lü, WL; Zhu, QG, 2010
)
0.36
"5 h, which necessitates regular dosing with intervals that do not exceed 7 days."( Erythropoietin encapsulation in chitosan nanoparticles and kinetics of drug release.
Bokharaei, M; Freeman, DJ; Margaritis, A; Xenocostas, A, 2011
)
0.37
" It was also observed that The RAPA entrapment efficiency reached its highest at 20% of addition dosage of RAPA."( High entrapment efficiency of chitosan/polylactic acid/tripolyphotspate nanosized microcapsules for rapamycin by an emulsion-evaporation approach.
Deng, Y; Fu, J; He, N; Jin, S; Wang, D; Wang, H; Wang, T; Yang, W, 2010
)
0.36
" The obtained results indicate that chitosan is a suitable polymer for developing a sustained-release dosage form of clotrimazole for local delivery."( Preparation and in vitro evaluation of chitosan microgranules with clotrimazole.
Szymańska, E; Winnicka, K,
)
0.13
"To have advantages of reduced dosing frequency, improved bioavailability and effective delivery system of Cefuroxime Axetil, a Chitosan based intragastric sustained release microbead formulation of Cefuroxime Axetil was developed."( Chitosan-based intragastric delivery of cefuroxime axetil: development and in-vitro evaluation of mucoadhesive approach.
Nagar, M; Yadav, AV, 2012
)
0.38
" Model simulations of analog:dNTP molar ratios using IPERGAY dosing suggested that FTC significantly contributes to the protective effect of preexposure prophylaxis (PrEP)."( Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; Kiser, JJ; MaWhinney, S; Seifert, SM; Zheng, JH, 2016
)
0.43
" The combination dosage form increased the blood glucose lowering extent of insulin and blood insulin level compared with nanoparticles or beads alone."( Alginate-C18 Conjugate Nanoparticles Loaded in Tripolyphosphate-Cross-Linked Chitosan-Oleic Acid Conjugate-Coated Calcium Alginate Beads as Oral Insulin Carrier.
Alfatama, M; Lim, LY; Wong, TW, 2018
)
0.48
" However, the short duration of action (< 2 h) of marketed dosage forms limit their ability to meet clinical needs."( Lidocaine tripotassium phosphate complex laden microemulsion for prolonged local anaesthesia: In vitro and in vivo studies.
Desai, AR; Desai, DT; Maulvi, FA; Patel, HP; Patel, KP; Pillai, LV; Ranch, KM; Shah, DO; Shah, SA; Shukla, MR, 2020
)
0.56
" Reducing the overall dose of sorafenib through injectable dosage form to release sustainably is of therapeutically more important to combat drug-induced toxicity."( Development of Formulation Methods and Physical Characterization of Injectable Sodium Selenite Nanoparticles for the Delivery of Sorafenib tosylate.
Alam, MF; Elmobark, ME; Makeen, HA; Moni, SS; Safhi, MM; Sultan, MH, 2020
)
0.56
"The novel injectable sorafenib loaded sodium selenite nanoparticle dosage form will serve better than conventional oral dosage form to elicit a safe therapeutic effect."( Development of Formulation Methods and Physical Characterization of Injectable Sodium Selenite Nanoparticles for the Delivery of Sorafenib tosylate.
Alam, MF; Elmobark, ME; Makeen, HA; Moni, SS; Safhi, MM; Sultan, MH, 2020
)
0.56
"TAF-DBS was a randomized, crossover clinical study of TFV-DP in DBS, following directly observed dosing of 33%, 67%, or 100% of daily TAF (25 mg)/FTC (200 mg)."( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020
)
0.56
" Together, these moieties provide complementary measures of cumulative adherence and recent dosing for TAF/FTC."( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020
)
0.56
" This approach has important assumptions, but indicates that, despite rapid clearance of the parent from plasma, sufficient intracellular FAVI-RTP may be maintained across the dosing interval because of its long intracellular half-life."( Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
Khoo, SH; Owen, A; Pertinez, H; Rajoli, RKR, 2021
)
0.62
" Here, we explained the mechanism behind the failure of molnupiravir in hospitalized patients and identified alternative dosing strategies that would improve therapeutic outcomes in all patients with COVID-19."( Why Molnupiravir Fails in Hospitalized Patients.
Brown, AN; Bulitta, JB; Drusano, GL; Franco, EJ; Hanrahan, KC; Lang, Y; Zhou, J, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
phosphorus oxoacidA pnictogen oxoacid which contains phosphorus and oxygen, at least one hydrogen atom bound to oxygen, and forms an ion by the loss of one or more protons.
acyclic phosphorus acid anhydride
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (10)

PathwayProteinsCompounds
Pterine Biosynthesis820
DOPA-Responsive Dystonia820
Hyperphenylalaninemia Due to Guanosine Triphosphate Cyclohydrolase Deficiency820
Hyperphenylalaninemia Due to 6-Pyruvoyltetrahydropterin Synthase Deficiency (ptps)820
Hyperphenylalaninemia Due to DHPR-Deficiency820
Segawa Syndrome820
Sepiapterin Reductase Deficiency820
Adenosylcobalamin Salvage from Cobinamide1219
Folate metabolism ( Folate metabolism )2039
Drosopterin and Aurodrosopterin Biosynthesis415

Research

Studies (974)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990232 (23.82)18.7374
1990's25 (2.57)18.2507
2000's146 (14.99)29.6817
2010's409 (41.99)24.3611
2020's162 (16.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.88 (24.57)
Research Supply Index6.94 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index37.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (1.97%)5.53%
Reviews18 (1.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational2 (0.20%)0.25%
Other973 (96.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]